Working… Menu

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03331562
Recruitment Status : Completed
First Posted : November 6, 2017
Last Update Posted : October 8, 2020
Stand Up To Cancer
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Translational Genomics Research Institute

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 29, 2020
Actual Study Completion Date : July 10, 2020